Skip to content

Epidemiological Survey on Prostate Cancer Screening Among the Target Population in Northern Guangzhou

Epidemiological Survey on Prostate Cancer Screening Among the Target Population in Northern Guangzhou

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113539
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frequent micturition, urgent micturition, dysuria

Interventions

Sponsors

Huadu District Peoples Hospital of Guangzhou
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Male individuals with an expected life expectancy of over 10 years, who can understand the pros and cons of prostate cancer screening and sign the informed consent form, and meet one of the following conditions: 2. Age >=50 years old; 3. Men with a family history of precancerous adenocarcinoma, aged 45 or above; 4. Age > 40 years old and baseline PSA > 1µg/L;

Exclusion criteria

Exclusion criteria: 1.Female population; 2.Population aged < 50 years old; 3.Patients with prostate cancer; 4.Population who have taken finasteride, saw palmetto, and certain herbal preparations within 3 months before screening—substances known to affect serum PSA levels; 5.Population who had acute prostatitis or acute urinary retention within 2 weeks before screening, received prostate massage within 1 week, underwent prostate-stimulating clinical procedures or behaviors (such as digital rectal examination [DRE], transurethral cystoscopy, or catheterization) within 2 days, or had ejaculation within 24 hours; 6.Population who refuse to cooperate with this study or cannot complete follow-up; 7.Population who have undergone orchiectomy or have cryptorchidism;

Design outcomes

Primary

MeasureTime frame
Screening positive rate;

Secondary

MeasureTime frame
Screening cost-benefit analysis;The participation rate and compliance of the screened subjects;The sensitivity of prostate screening;Positive predictive value;Negative predictive value;The specificity of prostate screening;

Countries

China

Contacts

Public ContactXi Ming

Huadu District Peoples Hospital of Guangzhou

bulesimon@sina.com+86 20 62935366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026